A partial loss-of-function variant in STAT6 protects against type 2 asthma

Area of Science:

• Immunology
• Genetics

Background:

• Signal transducer and activator of transcription 6 (STAT6) is crucial for type 2 (T2) inflammation.
• STAT6 pathway dysregulation is implicated in allergic diseases and asthma.
• Noncoding variants in STAT6 are linked to T2 inflammatory traits.

Purpose of the Study:

• To investigate the association of the rare STAT6 missense variant, p.L406P, with T2 inflammatory traits.
• To determine the effect of p.L406P on asthma and allergic disease risk.
• To functionally characterize the impact of p.L406P on STAT6 activity in cellular models.

Main Methods:

• Association analysis of p.L406P with clinical phenotypes (plasma protein levels, blood cell counts, disease risk).
• Functional studies in cell lines to assess STAT6 protein activity.
• Analysis of CD4+ T-cell responses in variant carriers versus non-carriers.

Main Results:

• p.L406P was associated with reduced STAT6 and IgE levels, and lower eosinophil/basophil counts.
• The variant conferred protection against asthma, particularly severe T2-high asthma.
• Functional assays demonstrated impaired IL-4-induced STAT6 activation and downstream gene expression changes in carriers.

Conclusions:

• The p.L406P variant acts as a partial loss-of-function allele for STAT6.
• Dampened IL-4 signaling due to p.L406P contributes to protection from T2-high asthma.
• STAT6 represents a promising therapeutic target for T2-high inflammatory conditions.